Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(14 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
−
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
−
current items will be put into the subsections.
 
  
−
*[[reviews on covid drug development]]
+
*'''[[scouting ideas]]'''
−
*[[scouting ideas]]
+
  
−
*[[Patients on biologicals]]
+
*'''[[PHA Biologicals]]'''
−
*[[HMGB1, RAGE]]
+
−
*[[pre-Interleukin 6]]
+
−
*[[post-Interleukin 6]]
+
−
*[[pre-TNFalpha]]
+
−
*[[post-TNFalpha]]
+
−
*[[pre-Interleukin 17]]
+
−
*[[post-Interleukin 17]]
+
−
*[[pre-Interleukin 1]]
+
−
*[[post-Interleukin 1]]
+
−
*[[Inflammasome]] ''colchicine''
+
−
*[[Methotrexate]]
+
−
*[[other anti-inflammatory]]
+
−
*[[NK-kappaB]]
+
−
*[[STAT 3]]
+
−
*[[JAK Janus Kinase]]
+
−
*[[Corticosteroids]]
+
−
*[[Cytokine absorbers]]
+
−
*[[Target Complement system]]
+
−
*[[Target Extracellular traps]]
+
−
*[[Target Neurophils]]
+
−
*[[Target Mast cells]] and kinins
+
−
*[[TGF beta]]
+
−
*[[Immunosuppressants]]
+
−
*[[Anticoagulant in covid19]]
+
−
*[[Antioxidants]]
+
−
*[[HIF-EPO-Iron]]
+
−
*[[Stem cells]]
+
−
*[[MDSC cells]]
+
−
*[[Interferons]]
+
−
*[[cAMP cGMP PDE NO]]
+
−
*[[TRPV* channels]]
+
−
*[[Retinoids]]
+
−
*[[Protease inhibitors]]
+
−
*[[Tyrosine kinase inhibitors]]
+
−
*[[Antineoplastic agents, traditional]]
+
−
*[[Mouthrinses]]
+
−
*[[Adenosinergic signaling]]
+
−
*[[Purinergic signaling]]
+
−
*[[Nicotinergic signaling]]
+
  
 +
*'''[[PHA conventional pharmacology]]'''
  
−
*[[other single compounds]]
+
*'''[[PHA retargeted compounds]]'''
−
*[[Retargeted Psychopharm]]
+
−
*[[Hydroxychloroquine]]
+
−
*
+
−
*[[Target ACE2, Spike protein]]
+
−
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
+
−
*[[other antiviral compounds]]
+
−
*[[AV Remdesivir]]
+
−
*[[AV Lopinavir]]
+
−
*[[AV Ivermectin]]
+
−
*[[AV Arabidol]]
+
−
*[[AV Favipiravir]]
+
  
−
*[[Antibiotics]]
+
*'''[[PHA antivirals by mechanism]]'''
  
 +
*'''[[PHA pharmacophore by screened target]]'''
  
−
*[[Vitamin D]]
+
*'''[[PHA ImmunoNutrients]]
−
*[[Anorganic nutrients Magnesium]]
+
−
*[[Anorganic nutrients Selenium]]
+
−
*[[Anorganic nutrients Zinc]]
+
−
*[[Anorganic nutrients Lithium]]
+
−
*[[Anorganic nutrients Copper]]
+
−
*[[Anorganic nutrients Bismuth]]
+
−
*[[Nutrition, general]]
+
−
*[[Exercise, Vibration]]
+
  
 +
*'''[[PHA compl altern natural]]'''
  
−
*[[Traditional Chinese Medicine]]
+
*'''[[PHA within indications compounds]]'''
−
*[[Natural compounds]]
+
  
−
*[[Statins]]
+
*'''[[PHA Serum products]]'''
−
*[[Antidiabetic compounds, any]]
+
−
*[[RSP - On RAS drugs]]
+
−
*[[RSP - On NSAIDs]]
+
  
−
*[[Reconvalescent blood products, Passive vaccine]]  
+
*'''[[PHA Vaccination]]'''
−
*[[Plasmapheresis]]
+
 
 +
PHA related options:
  
−
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
 
*[[Radiation therapy]]
 
*[[Radiation therapy]]
 
*[[Phototherapy]]
 
*[[Phototherapy]]
−
*[[Active vaccine]]  
+
*[[Electric fields]]
−
 
+
 
*[[Treatment other concepts]]
 
*[[Treatment other concepts]]
−
----
 
−
 
−
 
−
{{tp|p=32628145|t=2020. Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?|pdf=|usr=012}}
 
−
{{tp|p=32634024|t=2020. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32646061|t=2020. Could Ergothioneine Aid in the Treatment of Coronavirus Patients?|pdf=|usr=012}}
 
−
{{tp|p=32638906|t=2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.|pdf=|usr=012}}
 
−
{{tp|p=32645994|t=2020. Ten-Year Research Update Review: Antiviral Activities from Marine Organisms.|pdf=|usr=012}}
 
−
{{tp|p=32649880|t=2020. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.|pdf=|usr=012}}
 
−
{{tp|p=32641681|t=2020. Is hydroxychloroquine beneficial for COVID-19 patients?|pdf=|usr=012}}
 
−
{{tp|p=32638908|t=2020. Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era.|pdf=|usr=012}}
 
−
{{tp|p=32646869|t=2020. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.|pdf=|usr=012}}
 
−
{{tp|p=32646499|t=2020. Effect of favipiravir and an anti-inflammatory strategy for COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32631373|t=2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32620147|t=2020. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.|pdf=|usr=012}}
 
−
{{tp|p=32618691|t=2020. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2.|pdf=|usr=012}}
 
−
{{tp|p=32640414|t=2020. Vitamin D deficiency in patients with diabetes and COVID- 19 infection.|pdf=|usr=012}}
 
−
{{tp|p=32634717|t=2020. Application of Artificial Intelligence in COVID-19 drug repurposing.|pdf=|usr=012}}
 
−
{{tp|p=32639233|t=2020. Concentration-dependent mortality of chloroquine in overdose.|pdf=|usr=012}}
 
−
{{tp|p=32619390|t=2020. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.|pdf=|usr=012}}
 
−
{{tp|p=32615862|t=2020. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.|pdf=|usr=012}}
 
−
{{tp|p=32616599|t=2020. Potential of regulatory T cell-based therapies in the management of severe COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32640331|t=2020. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease.|pdf=|usr=012}}
 
−
{{tp|p=32621202|t=2020. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.|pdf=|usr=012}}
 
−
{{tp|p=32638628|t=2020. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.|pdf=|usr=012}}
 
−
{{tp|p=32622993|t=2020. Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.|pdf=|usr=012}}
 
−
{{tp|p=32621881|t=2020. INCIDENCE OF ARRHYTHMIAS AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN SYMPTOMATIC PEDIATRIC PATIENTS WITH PCR POSITIVE SARS-CoV-2 INFECTION INCLUDING DRUG INDUCED CHANGES IN THE CORRECTED QT INTERVAL (QTc).|pdf=|usr=012}}
 
−
{{tp|p=32641876|t=2020. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.|pdf=|usr=012}}
 
−
{{tp|p=32641874|t=2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.|pdf=|usr=012}}
 
−
{{tp|p=32643111|t=2020. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.|pdf=|usr=012}}
 
−
{{tp|p=32640381|t=2020. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.|pdf=|usr=012}}
 
−
{{tp|p=32642806|t=2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.|pdf=|usr=012}}
 
−
{{tp|p=32645633|t=2020. An update on antiviral antibody-based biopharmaceuticals.|pdf=|usr=012}}
 
−
{{tp|p=32645632|t=2020. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32634603|t=2020. COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.|pdf=|usr=012}}
 
−
{{tp|p=32646770|t=2020. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.|pdf=|usr=012}}
 
−
{{tp|p=32639711|t=2020. CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.|pdf=|usr=012}}
 
−
{{tp|p=32619190|t=2020. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32648245|t=2020. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.|pdf=|usr=012}}
 
−
{{tp|p=32628223|t=2020. Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections.|pdf=|usr=012}}
 
−
{{tp|p=32640172|t=2020. Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept.|pdf=|usr=012}}
 
−
{{tp|p=32634026|t=2020. COVID-19 Clinical Trials: Unravelling a Methodological Gordian Knot.|pdf=|usr=012}}
 
−
{{tp|p=32628535|t=2020. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.|pdf=|usr=012}}
 
−
{{tp|p=32647027|t=2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.|pdf=|usr=012}}
 
−
{{tp|p=32632035|t=2020. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.|pdf=|usr=012}}
 
−
{{tp|p=32632034|t=2020. COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study.|pdf=|usr=012}}
 
−
{{tp|p=32632030|t=2020. Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al.|pdf=|usr=012}}
 
−
{{tp|p=32620597|t=2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.|pdf=|usr=012}}
 
−
{{tp|p=32641296|t=2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.|pdf=|usr=012}}
 
−
{{tp|p=32631826|t=2020. Clinical trials of repurposed antivirals for SARS-CoV-2.|pdf=|usr=012}}
 
−
{{tp|p=32639103|t=2020. Trainee Led Collaboratives, Clinical Trials And New Opportunities In The Covid-19 Era.|pdf=|usr=012}}
 
−
{{tp|p=32644876|t=2020. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus.|pdf=|usr=012}}
 
−
{{tp|p=32646867|t=2020. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.|pdf=|usr=012}}
 
−
{{tp|p=32631851|t=2020. Urgent call for greater multilateralism and coordination of covid-19 trials.|pdf=|usr=012}}
 
−
{{tp|p=32631850|t=2020. Covid-19: research methods must be flexible in a crisis.|pdf=|usr=012}}
 
−
{{tp|p=32620554|t=2020. Dexamethasone in the management of covid -19.|pdf=|usr=012}}
 
−
{{tp|p=32611587|t=2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.|pdf=|usr=012}}
 
−
{{tp|p=32641344|t=2020. COVID-19 clinical trials: see it big and keep it simple.|pdf=|usr=012}}
 
−
{{tp|p=32639062|t=2020. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32627226|t=2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?|pdf=|usr=012}}
 
−
{{tp|p=32645204|t=2020. Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2.|pdf=|usr=012}}
 
−
{{tp|p=32621754|t=2020. COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.|pdf=|usr=012}}
 
−
{{tp|p=32639031|t=2020. Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19?|pdf=|usr=012}}
 
−
{{tp|p=32640179|t=2020. Current Therapies Under Investigation for COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32633733|t=2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.|pdf=|usr=012}}
 
−
{{tp|p=32613971|t=2020. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.|pdf=|usr=012}}
 
−
{{tp|p=32621392|t=2020. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.|pdf=|usr=012}}
 
−
{{tp|p=32640049|t=2020. Immune checkpoint inhibition in the era of COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32640019|t=2020. Proposing minimum requirements for announcing clinical trial results during the COVID-19 pandemic.|pdf=|usr=012}}
 
−
{{tp|p=32628748|t=2020. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.|pdf=|usr=012}}
 
−
{{tp|p=32648959|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.|pdf=|usr=012}}
 
−
{{tp|p=32634894|t=2020. Smoking in critically ill patients with COVID-19: the Australian experience.|pdf=|usr=012}}
 
−
{{tp|p=32628049|t=2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32619167|t=2020. Effect of the Phytochemical Agents Against the SARS-CoV and Selected Some of them for Application to COVID-19: A Mini-Review.|pdf=|usr=012}}
 
−
{{tp|p=32634080|t=2020. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
 
−
{{tp|p=32634079|t=2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.|pdf=|usr=012}}
 
−
{{tp|p=32628591|t=2020. Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.|pdf=|usr=012}}
 
−
{{tp|p=32648845|t=2020. Therapeutic targets and computational approaches on drug development for COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32621718|t=2020. Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation.|pdf=|usr=012}}
 
−
{{tp|p=32643448|t=2020. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32632960|t=2020. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.|pdf=|usr=012}}
 
−
{{tp|p=32629169|t=2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.|pdf=|usr=012}}
 
−
{{tp|p=32616659|t=2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32616658|t=2020. BET 1: Lopinavir-ritonavir and COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32641191|t=2020. Bacillus Calmette-Guerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study.|pdf=|usr=012}}
 
−
{{tp|p=32648935|t=2020. SGLT2 inhibition and COVID-19: The road not taken.|pdf=|usr=012}}
 
−
{{tp|p=32620680|t=2020. Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?|pdf=|usr=012}}
 
−
{{tp|p=32631083|t=2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32643980|t=2020. Predictor of poor prognosis of COVID-19 patients----liver injury.|pdf=|usr=012}}
 
−
{{tp|p=32649840|t=2020. Liver injury in severe COVID-19 infection: current insights and challenges.|pdf=|usr=012}}
 
−
{{tp|p=32639083|t=2020. Balancing infection control and frailty prevention during and after the COVID-19 pandemic: Introduction of the NCGG Home Exercise Program for Older People 2020.|pdf=|usr=012}}
 
−
{{tp|p=32645727|t=2020. Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?|pdf=|usr=012}}
 
−
{{tp|p=32643512|t=2020. Thinking more about therapy with convalescent plasma for COVID-19 patients.|pdf=|usr=012}}
 
−
{{tp|p=32633162|t=2020. Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.|pdf=|usr=012}}
 
−
{{tp|p=32643997|t=2020. Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32615877|t=2020. Suggestions for Combatting COVID-19 by Natural Means in the Absence of Standard Medical Regimens.|pdf=|usr=012}}
 
−
{{tp|p=32649272|t=2020. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?|pdf=|usr=012}}
 
−
{{tp|p=32643552|t=2020. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.|pdf=|usr=012}}
 
−
{{tp|p=32643550|t=2020. Potential of NO donor furoxan as SARS-CoV-2 main protease (M(pro)) inhibitors: in silico analysis.|pdf=|usr=012}}
 
−
{{tp|p=32643529|t=2020. Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery.|pdf=|usr=012}}
 
−
{{tp|p=32627715|t=2020. Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study.|pdf=|usr=012}}
 
−
{{tp|p=32627689|t=2020. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.|pdf=|usr=012}}
 
−
{{tp|p=32619162|t=2020. Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.|pdf=|usr=012}}
 
−
{{tp|p=32619134|t=2020. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach.|pdf=|usr=012}}
 
−
{{tp|p=32618198|t=2020. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.|pdf=|usr=012}}
 
−
{{tp|p=32643158|t=2020. Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach.|pdf=|usr=012}}
 
−
{{tp|p=32643200|t=2020. Convalescent plasma therapy in patients with COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32647045|t=2020. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.|pdf=|usr=012}}
 
−
{{tp|p=32644254|t=2020. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.|pdf=|usr=012}}
 
−
{{tp|p=32644224|t=2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.|pdf=|usr=012}}
 
−
{{tp|p=32644208|t=2020. Erythropoietin Induced Hemoglobin Sub-Unit Beta may Stimulate Innate Immune RNA Virus Pattern Recognition, Suppress Reactive Oxygen Species, Reduce ACE2 Viral Doorway Opening and Neutrophil Extracellular Traps against Covid-19.|pdf=|usr=012}}
 
−
{{tp|p=32633865|t=2020. A retrospective review of memantine use and COVID-19-associated mortality from a national database.|pdf=|usr=012}}
 
−
{{tp|p=32633831|t=2020. RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.|pdf=|usr=012}}
 
−
{{tp|p=32621621|t=2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.|pdf=|usr=012}}
 
−
{{tp|p=32617989|t=2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=012}}
 
−
 
−
{{tp|p=32634602|t=2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.|pdf=|usr=012}}
 
−
{{tp|p=32629115|t=2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.|pdf=|usr=012}}
 
−
{{tp|p=32619764|t=2020. Case reports study of the first five patients COVID-19 treated with remdesivir in France.|pdf=|usr=012}}
 
−
{{tp|p=32634589|t=2020. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.|pdf=|usr=012}}
 
−
{{tp|p=32623082|t=2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32623080|t=2020. An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.|pdf=|usr=012}}
 
−
{{tp|p=32629817|t=2020. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review.|pdf=|usr=012}}
 
−
{{tp|p=32617855|t=2020. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.|pdf=|usr=012}}
 
−
{{tp|p=32627127|t=2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.|pdf=|usr=012}}
 
−
{{tp|p=32623068|t=2020. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective.|pdf=|usr=012}}
 
−
{{tp|p=32634126|t=2020. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.|pdf=|usr=012}}
 
−
{{tp|p=32629768|t=2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.|pdf=|usr=012}}
 
−
{{tp|p=32630746|t=2020. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.|pdf=|usr=012}}
 
−
{{tp|p=32622963|t=2020. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? ().|pdf=|usr=012}}
 
−
{{tp|p=32622008|t=2020. Azithromycin and SARS-CoV-2 infection: where we are now and where we are going.|pdf=|usr=012}}
 
−
{{tp|p=32636240|t=2020. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.|pdf=|usr=012}}
 
−
{{tp|p=32611687|t=2020. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32627442|t=2020. Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.|pdf=|usr=012}}
 
−
{{tp|p=32638109|t=2020. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?|pdf=|usr=012}}
 
−
{{tp|p=32646487|t=2020. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates.|pdf=|usr=012}}
 
−
{{tp|p=32635935|t=2020. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.|pdf=|usr=012}}
 
−
{{tp|p=32631442|t=2020. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
 
−
{{tp|p=32650019|t=2020. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32629788|t=2020. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.|pdf=|usr=012}}
 
−
{{tp|p=32610445|t=2020. Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)).|pdf=|usr=012}}
 
−
{{tp|p=32634550|t=2020. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.|pdf=|usr=012}}
 
−
{{tp|p=32641037|t=2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.|pdf=|usr=012}}
 
−
{{tp|p=32647131|t=2020. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.|pdf=|usr=012}}
 
−
{{tp|p=32648153|t=2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.|pdf=|usr=012}}
 
−
{{tp|p=32641560|t=2020. COVID-19 and vitamin D deficiency, a fatal combination?|pdf=|usr=012}}
 
−
{{tp|p=32645974|t=2020. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.|pdf=|usr=012}}
 
−
{{tp|p=32619723|t=2020. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?|pdf=|usr=012}}
 
−
{{tp|p=32622723|t=2020. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.|pdf=|usr=012}}
 
−
{{tp|p=32629137|t=2020. Ultraviolet-based Biophotonic Technologies and COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32641511|t=2020. Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.|pdf=|usr=012}}
 
−
{{tp|p=32621829|t=2020. Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable".|pdf=|usr=012}}
 
−
{{tp|p=32638884|t=2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?|pdf=|usr=012}}
 
−
{{tp|p=32616763|t=2020. A candidate multi-epitope vaccine against SARS-CoV-2.|pdf=|usr=012}}
 
−
{{tp|p=32638647|t=2020. Alternative management of Covid-19 infection.|pdf=|usr=012}}
 
−
{{tp|p=32636116|t=2020. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.|pdf=|usr=012}}
 
−
{{tp|p=32645478|t=2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.|pdf=|usr=012}}
 
−
{{tp|p=32629139|t=2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".|pdf=|usr=012}}
 
−
{{tp|p=32635353|t=2020. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.|pdf=|usr=012}}
 
−
{{tp|p=32640619|t=2020. Prospects and Challenges in the Development of Universal Influenza Vaccines.|pdf=|usr=012}}
 
−
{{tp|p=32635180|t=2020. Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.|pdf=|usr=012}}
 
−
{{tp|p=32621841|t=2020. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.|pdf=|usr=012}}
 
−
{{tp|p=32629804|t=2020. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.|pdf=|usr=012}}
 
−
{{tp|p=32620700|t=2020. Low Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care.|pdf=|usr=012}}
 
−
{{tp|p=32623965|t=2020. Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?|pdf=|usr=012}}
 
−
{{tp|p=32628262|t=2020. The Development of COVID-19 Vaccines: Safeguards Needed.|pdf=|usr=012}}
 
−
{{tp|p=32628244|t=2020. Developing a SARS-CoV-2 Vaccine at Warp Speed.|pdf=|usr=012}}
 
−
{{tp|p=32614442|t=2020. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32613691|t=2020. Editorial - Nutritional Status Affects COVID-19 Patient Outcomes.|pdf=|usr=012}}
 
−
{{tp|p=32613660|t=2020. Evaluation of Nutritional Risk and its Association With Mortality Risk in Severe and Critically Ill COVID-19 Patients.|pdf=|usr=012}}
 
−
{{tp|p=32619276|t=2020. Low dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity?|pdf=|usr=012}}
 
−
{{tp|p=32619669|t=2020. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.|pdf=|usr=012}}
 
−
{{tp|p=32633860|t=2020. Safety of Plasma Infusions in Parkinson's Disease.|pdf=|usr=012}}
 
−
{{tp|p=32649078|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.|pdf=|usr=012}}
 
−
{{tp|p=32649077|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 
−
{{tp|p=32649076|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 
−
{{tp|p=32649075|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 
−
{{tp|p=32649074|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 
−
{{tp|p=32643410|t=2020. Bioactive compounds from marine resources against novel corona virus (2019-nCoV): in silico study for corona viral drug.|pdf=|usr=012}}
 
−
{{tp|p=32636505|t=2020. COVID-19 platform trial delivers.|pdf=|usr=012}}
 
−
{{tp|p=32623442|t=2020. Going back in time for an antibody to fight COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32645305|t=2020. Golden Anniversary of the Nicotinic Receptor.|pdf=|usr=012}}
 
−
{{tp|p=32618794|t=2020. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
 
−
{{tp|p=32615642|t=2020. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests.|pdf=|usr=012}}
 
−
{{tp|p=32613637|t=2020. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.|pdf=|usr=012}}
 
−
{{tp|p=32648294|t=2020. COVID-19: Phylogenetic approaches may help in finding resources for natural cure.|pdf=|usr=012}}
 
−
{{tp|p=32647056|t=2020. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
 
−
{{tp|p=32648313|t=2020. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=012}}
 
−
{{tp|p=32614102|t=2020. Using heat to kill SARS-CoV-2.|pdf=|usr=012}}
 
−
{{tp|p=32646977|t=2020. Can interferons stop COVID-19 before it takes hold?|pdf=|usr=012}}
 
−
{{tp|p=32649367|t=2020. Potential Immunotherapeutic Targets For Hypoxia Due to COVI-FLU.|pdf=|usr=012}}
 
−
{{tp|p=32619318|t=2020. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.|pdf=|usr=012}}
 
−
{{tp|p=32627216|t=2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.|pdf=|usr=012}}
 
−
{{tp|p=32639598|t=2020. SARS-CoV2 and immunosuppression: a double-edged sword.|pdf=|usr=012}}
 
−
{{tp|p=32629531|t=2020. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.|pdf=|usr=012}}
 
−
{{tp|p=32614684|t=2020. Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs.|pdf=|usr=012}}
 
−
 
−
{{tp|p=32388537|t=2020. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).|pdf=|usr=009}}
 
−
{{tp|p=32532959|t=2020. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin.|pdf=|usr=009}}
 
−
{{tp|p=32423553|t=2020. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.|pdf=|usr=009}}
 
−
{{tp|p=32531235|t=2020. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.|pdf=|usr=009}}
 
−
{{tp|p=32430279|t=2020. Gut microbiota and Covid-19- possible link and implications.|pdf=|usr=009}}
 
−
{{tp|p=32416259|t=2020. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.|pdf=|usr=009}}
 
−
{{tp|p=32558150|t=2020. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.|pdf=|usr=010}}
 
−
{{tp|p=32585135|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=010}}
 
−
{{tp|p=32546195|t=2020. Micronutrient status of COVID-19 patients: a critical consideration.|pdf=|usr=010}}
 
−
{{tp|p=32559343|t=2020. Rationale for targeting Complement in COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32543705|t=2020. Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition.|pdf=|usr=010}}
 
−
{{tp|p=32592394|t=2020. A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.|pdf=|usr=010}}
 
−
{{tp|p=32590326|t=2020. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.|pdf=|usr=010}}
 
−
{{tp|p=32562814|t=2020. Statins and other drugs: Facing COVID-19 as a vascular disease.|pdf=|usr=010}}
 
−
{{tp|p=32424591|t=2020. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?|pdf=|usr=011}}
 
−
{{tp|p=32598884|t=2020. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge.|pdf=|usr=011}}
 
−
{{tp|p=32481719|t=2020. The Role of MicroRNA in the Airway Surface Liquid Homeostasis.|pdf=|usr=011}}
 
−
{{tp|p=32534506|t=2020. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?|pdf=|usr=011}}
 
−
{{tp|p=32600316|t=2020. The cholinergic anti-inflammatory pathway alleviates acute lung injury.|pdf=|usr=011}}
 
−
{{tp|p=32537478|t=2020. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD.|pdf=|usr=011}}
 
−
{{tp|p=32595361|t=2020. Gut-lung axis and dysbiosis in COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32591496|t=2020. Door to the cell for COVID-19 opened, leading way to therapies.|pdf=|usr=011}}
 
−
{{tp|p=32602262|t=2020. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.|pdf=|usr=011}}
 
−
{{tp|p=32555145|t=2020. Targeting the entry step of SARS-CoV-2: a promising therapeutic approach.|pdf=|usr=011}}
 
−
{{tp|p=32594085|t=2020. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32582574|t=2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.|pdf=|usr=011}}
 
−
{{tp|p=32545271|t=2020. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.|pdf=|usr=011}}
 
−
{{ttp|p=32593832|t=2020. Why is SARS-CoV-2 infection more severe in obese men? The gut lymphatics - Lung axis hypothesis.|pdf=|usr=011}}
 
−
{{tp|p=32573788|t=2020. Elucidation of Cellular Targets and Exploitation of the Receptor Binding Domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.|pdf=|usr=011}}
 
−
{{tp|p=32551652|t=2020. Critical Differences Between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.|pdf=|usr=011}}
 
−
{{tp|p=32551648|t=2020. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.|pdf=|usr=011}}
 
−
{{tp|p=32571797|t=2020. Identification of common deletions in the spike protein of SARS-CoV-2.|pdf=|usr=011}}
 
−
{{tp|p=32606248|t=2020. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface.|pdf=|usr=011}}
 
−
{{tp|p=32602627|t=2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=011}}
 
−
 
−
{{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
 
  
−
{{tp|p=32167678|t=2020. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.|pdf=|usr=013}}
 
−
{{tp|p=32405233|t=2020. The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection.|pdf=|usr=013}}
 
−
{{tp|p=32400027|t=2020. Immunological fortification at our barrier organs: Protecting us as we age.|pdf=|usr=013}}
 
−
{{tp|p=25762305|t=2015. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.|pdf=|usr=013}}
 
−
{{tp|p=32621997|t=2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?|pdf=|usr=013}}
 
−
{{tp|p=32621996|t=2020. HCQ induced QT prolongation- Primum non nocere.|pdf=|usr=013}}
 
−
{{tp|p=32651941|t=2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.|pdf=|usr=013}}
 
−
{{tp|p=32645630|t=2020. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.|pdf=|usr=013}}
 
−
{{tp|p=32430515|t=2020. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung.|pdf=|usr=013}}
 
−
{{tp|p=32654006|t=2020. Emerging pharmacological therapies for ARDS: COVID-19 and beyond.|pdf=|usr=013}}
 
−
{{tp|p=32303896|t=2020. Therapeutic and prophylactic potential of anti-microbial peptides against coronaviruses.|pdf=|usr=013}}
 
−
{{tp|p=32622261|t=2020. Current Status of COVID-19 Therapies and Drug Repositioning Applications.|pdf=|usr=013}}
 
−
{{tp|p=32652194|t=2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.|pdf=|usr=013}}
 
−
{{tp|p=32339702|t=2020. Role of phototherapy in the era of biologics.|pdf=|usr=013}}
 
−
{{tp|p=32622513|t=2020. The roles of PPARgamma and its agonists in autoimmune diseases: A comprehensive review.|pdf=|usr=013}}
 
−
{{tp|p=32624376|t=2020. Ayurvedic clinical profile of COVID-19 - A preliminary report.|pdf=|usr=013}}
 
−
{{tp|p=32637368|t=2020. COVID-19: Introducing Low Dose Radiation as an Effective Treatment for Pneumonia that Shouldn't Induce Selective Pressure and New Mutations.|pdf=|usr=013}}
 
−
{{tp|p=32375574|t=2020. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.|pdf=|usr=013}}
 
−
{{tp|p=32306854|t=2020. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective.|pdf=|usr=013}}
 
−
{{tp|p=18442051|t=2008. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.|pdf=|usr=013}}
 
−
{{tp|p=32655741|t=2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.|pdf=|usr=013}}
 
−
{{tp|p=32617428|t=2020. Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence.|pdf=|usr=013}}
 
−
{{tp|p=15693056|t=2005. SARS-CoV protease inhibitors design using virtual screening method from natural products libraries.|pdf=|usr=013}}
 
−
{{tp|p=32594451|t=2020. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.|pdf=|usr=013}}
 
−
{{tp|p=32535155|t=2020. The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection.|pdf=|usr=013}}
 
−
{{tp|p=32652164|t=2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.|pdf=|usr=013}}
 
−
{{tp|p=28864360|t=2018. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.|pdf=|usr=013}}
 
−
{{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=013}}
 
−
{{tp|p=18324609|t=2008. Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry.|pdf=|usr=013}}
 
−
{{tp|p=32398885|t=2020. How materials can beat a virus.|pdf=|usr=013}}
 
−
{{tp|p=32398884|t=2020. Materials Science in the time of Coronavirus.|pdf=|usr=013}}
 
−
{{tp|p=32410212|t=2020. Acute kidney injury is associated with the mortality of coronavirus disease 2019.|pdf=|usr=013}}
 
−
{{tp|p=32628003|t=2020. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.|pdf=|usr=013}}
 
−
{{tp|p=32617527|t=2020. Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV).|pdf=|usr=013}}
 
−
{{tp|p=32301512|t=2020. Drug repositioning: a brief overview.|pdf=|usr=013}}
 
−
{{tp|p=32653646|t=2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.|pdf=|usr=013}}
 
−
{{tp|p=32624302|t=2020. A case of cytokine hemofiltration and extracorporeal life support as treatment of coronavirus disease 2019 (COVID-19) respiratory failure.|pdf=|usr=013}}
 
−
{{tp|p=32642277|t=2020. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial.|pdf=|usr=013}}
 
−
{{tp|p=32642225|t=2020. Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19.|pdf=|usr=013}}
 
−
{{tp|p=32576276|t=2020. "Right-to-Try" experimental drugs: an overview.|pdf=|usr=013}}
 
−
{{tp|p=32650788|t=2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.|pdf=|usr=013}}
 
−
{{tp|p=32188729|t=2020. Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.|pdf=|usr=013}}
 
−
{{tp|p=18199635|t=2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.|pdf=|usr=013}}
 
−
{{tp|p=32493486|t=2020. Alveolar lipids in pulmonary disease. A review.|pdf=|usr=013}}
 
−
{{tp|p=32653736|t=2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.|pdf=|usr=013}}
 
−
{{tp|p=32423569|t=2020. Del empirismo a la evidencia cientifica en el tratamiento con antiviricos en los casos graves de infeccion por coronavirus en tiempos de epidemia.|pdf=|usr=013}}
 
−
{{tp|p=32599077|t=2020. Coronavirus vaccine-associated lung immunopathology-what is the significance?|pdf=|usr=013}}
 
−
{{tp|p=32600307|t=2020. The alpha7 nicotinic acetylcholine receptor agonist, GTS-21, attenuates hyperoxia-induced acute inflammatory lung injury by alleviating the accumulation of HMGB1 in the airways and the circulation.|pdf=|usr=013}}
 
−
{{tp|p=32579882|t=2020. Preparing for Pandemics: RNA Vaccines at the Forefront.|pdf=|usr=013}}
 
−
{{tp|p=32516954|t=2020. Antiviral Effects of Plant-Derived Essential Oils and Their Components: An Updated Review.|pdf=|usr=013}}
 
−
{{tp|p=32325742|t=2020. Advances on Antiviral Activity of Morus spp. Plant Extracts: Human Coronavirus and Virus-Related Respiratory Tract Infections in the Spotlight.|pdf=|usr=013}}
 
−
{{tp|p=32295300|t=2020. Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses.|pdf=|usr=013}}
 
−
{{tp|p=32459913|t=2020. Remdesivir - An Important First Step.|pdf=|usr=013}}
 
−
{{tp|p=32636478|t=2020. Dexamethasone to the rescue.|pdf=|usr=013}}
 
−
{{tp|p=32409740|t=2020. Type I and type III interferon in opposition?|pdf=|usr=013}}
 
−
{{tp|p=32378128|t=2020. Drug repurposing in cardiology.|pdf=|usr=013}}
 
−
{{tp|p=32651844|t=2020. The 'president's drug'.|pdf=|usr=013}}
 
−
{{tp|p=32643072|t=2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.|pdf=|usr=013}}
 
−
{{tp|p=32474177|t=2020. Nicotinic acetylcholine receptors regulate clustering, fusion and acidification of the rat brain synaptic vesicles.|pdf=|usr=013}}
 
−
{{tp|p=32529044|t=2020. Better patient identification could help fight the coronavirus.|pdf=|usr=013}}
 
−
{{tp|p=32655899|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=013}}
 
−
{{tp|p=32579137|t=2020. New international guidance on quality, safety and efficacy of DNA vaccines.|pdf=|usr=013}}
 
−
{{tp|p=32579135|t=2020. WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019.|pdf=|usr=013}}
 
−
{{tp|p=32536809|t=2020. Is a vitamin D fortification strategy needed?|pdf=|usr=013}}
 
−
{{tp|p=32349265|t=2020. Vitamin D and Immunity in Infants and Children.|pdf=|usr=013}}
 
−
{{tp|p=32344708|t=2020. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis.|pdf=|usr=013}}
 
−
{{tp|p=32325790|t=2020. Key Vitamin D Target Genes with Functions in the Immune System.|pdf=|usr=013}}
 
−
{{tp|p=32325778|t=2020. Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations.|pdf=|usr=013}}
 
−
{{tp|p=32290296|t=2020. The Role of Selenium in Health and Disease: Emerging and Recurring Trends.|pdf=|usr=013}}
 
−
{{tp|p=32617169|t=2020. Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.|pdf=|usr=013}}
 
−
{{tp|p=32551127|t=2020. Covering coronavirus-emerging tools for the fight against the common enemy.|pdf=|usr=013}}
 
−
{{tp|p=32653463|t=2020. Vaccines for COVID-19: The current state of play.|pdf=|usr=013}}
 
−
{{tp|p=32630514|t=2020. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection.|pdf=|usr=013}}
 
−
{{tp|p=32590098|t=2020. Global research on artemisinin and its derivatives: Perspectives from patents.|pdf=|usr=013}}
 
−
{{tp|p=32653650|t=2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.|pdf=|usr=013}}
 
−
{{tp|p=32653649|t=2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.|pdf=|usr=013}}
 
−
{{tp|p=32384116|t=2020. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.|pdf=|usr=013}}
 
−
{{tp|p=32350142|t=2020. News Feature: To counter the pandemic, clinicians bank on repurposed drugs.|pdf=|usr=013}}
 
−
{{tp|p=17567736|t=2007. Crystallographic studies of the complexes of antiviral protein griffithsin with glucose and N-acetylglucosamine.|pdf=|usr=013}}
 
−
{{tp|p=17340634|t=2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin.|pdf=|usr=013}}
 
−
{{tp|p=32540609|t=2020. Possible beneficial role of throat gargling in the coronavirus disease pandemic.|pdf=|usr=013}}
 
−
{{tp|p=32653040|t=2020. The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.|pdf=|usr=013}}
 
−
{{tp|p=32616298|t=2020. Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?|pdf=|usr=013}}
 
−
{{tp|p=32636066|t=2020. Electrocardiographic/QT interval monitoring with a portable device in hospitalized patients with COVID-19: a protocol proposal.|pdf=|usr=013}}
 
−
{{tp|p=32593625|t=2020. Melatonin, coronavirus, cardiovascular disease, and the geriatric emergency: let's use everything we have!|pdf=|usr=013}}
 
−
{{tp|p=32622732|t=2020. The presence of heart disease worsens prognosis in patients with COVID-19.|pdf=|usr=013}}
 
−
{{tp|p=32550880|t=2020. Recommandations EMA sur l'usage compassionnel du remdesivir.|pdf=|usr=013}}
 
−
{{tp|p=32537031|t=2020. Hochdosiertes Chloroquin bei COVID-19 gefahrlich.|pdf=|usr=013}}
 
−
{{tp|p=32577525|t=2020. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques.|pdf=|usr=013}}
 
−
{{tp|p=32179788|t=2020. Ginkgolic acid inhibits fusion of enveloped viruses.|pdf=|usr=013}}
 
−
{{tp|p=32448377|t=2020. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.|pdf=|usr=013}}
 
−
{{tp|p=32318958|t=2020. How to "Detronize" Virus in Crown - Questions to Current Stem Cell Therapies.|pdf=|usr=013}}
 
−
{{tp|p=32537523|t=2020. An aurora of natural products-based drug discovery is coming.|pdf=|usr=013}}
 
−
{{tp|p=32612804|t=2020. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.|pdf=|usr=013}}
 
−
{{tp|p=32641977|t=2020. Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19.|pdf=|usr=013}}
 
−
{{tp|p=32653199|t=2020. Immunomodulation for the management of corona virus disease (COVID-19).|pdf=|usr=013}}
 
−
{{tp|p=32631501|t=2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?|pdf=|usr=013}}
 
−
{{tp|p=32620409|t=2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.|pdf=|usr=013}}
 
−
{{tp|p=32636114|t=2020. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.|pdf=|usr=013}}
 
−
{{tp|p=32565057|t=2020. The true historical origin of convalescent plasma therapy.|pdf=|usr=013}}
 
−
{{tp|p=32542716|t=2020. Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products.|pdf=|usr=013}}
 
−
{{tp|p=32333396|t=2020. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.|pdf=|usr=013}}
 
−
{{tp|p=32533558|t=2020. Convalescent plasma - this is no time for competition.|pdf=|usr=013}}
 
−
{{tp|p=24117799|t=2014. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.|pdf=|usr=013}}
 
−
{{tp|p=32504825|t=2020. Innovative highlights of clinical drug trial design.|pdf=|usr=013}}
 
−
{{tp|p=32593869|t=2020. Traditional Chinese Herbal Medication for corona-virus 2019.|pdf=|usr=013}}
 
−
{{tp|p=32340868|t=2020. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?|pdf=|usr=013}}
 
−
{{tp|p=32651113|t=2020. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.|pdf=|usr=013}}
 
−
{{tp|p=32313527|t=2020. Vacunas contra el coronavirus.|pdf=|usr=013}}
 
−
{{tp|p=32395638|t=2020. Chloroquine/Hydroxychloroquine Overdose.|pdf=|usr=013}}
 
−
{{tp|p=32240549|t=2020. Pivotal role of convalescent plasma in managing emerging infectious diseases.|pdf=|usr=013}}
 
−
{{tp|p=12800213|t=2003. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome.|pdf=|usr=013}}
 
  
−
{{tp|p=32596616|t=2020. Extraction, Characterization, and Anticoagulant Activity of a Sulfated Polysaccharide from Bursatella leachii Viscera.|pdf=|usr=013}}
+
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
−
{{tp|p=32579890|t=2020. Targeting drug delivery in the vascular system: Focus on endothelium.|pdf=|usr=013}}
+
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
−
{{tp|p=32654004|t=2020. Comments on: The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality.|pdf=|usr=013}}
+
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
−
{{tp|p=32653224|t=2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?|pdf=|usr=013}}
+
Paper is (not yet in PubMed) :
−
{{tp|p=32624192|t=2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32502485|t=2020. Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.|pdf=|usr=013}}
+
−
{{tp|p=32653550|t=2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?|pdf=|usr=013}}
+
−
{{tp|p=32606531|t=2020. Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?|pdf=|usr=013}}
+
−
{{tp|p=32637086|t=2020. A severe refractory COVID-19 patient responding to convalescent plasma; A case series.|pdf=|usr=013}}
+
−
{{tp|p=32653425|t=2020. Does androgen deprivation therapy protect against severe complications from COVID-19?|pdf=|usr=013}}
+
−
{{tp|p=32653452|t=2020. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.|pdf=|usr=013}}
+
−
{{tp|p=32607398|t=2020. The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol.|pdf=|usr=013}}
+
−
{{tp|p=32600868|t=2020. Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19?|pdf=|usr=013}}
+
−
{{tp|p=32611537|t=2020. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.|pdf=|usr=013}}
+
−
{{tp|p=32603888|t=2020. Clinical implications of nicotine as an antimicrobial agent and immune modulator.|pdf=|usr=013}}
+
−
{{tp|p=32626733|t=2020. Effect of Thymoquinone on Acute Kidney Injury Induced by Sepsis in BALB/c Mice.|pdf=|usr=013}}
+
−
{{tp|p=32443566|t=2020. Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity.|pdf=|usr=013}}
+
−
{{tp|p=32120929|t=2020. Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63.|pdf=|usr=013}}
+
−
{{tp|p=32629280|t=2020. COVID19 inhibitors: A prospective therapeutics.|pdf=|usr=013}}
+
−
{{tp|p=22446091|t=2012. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.|pdf=|usr=013}}
+
−
{{tp|p=32297972|t=2020. Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts.|pdf=|usr=013}}
+
−
{{tp|p=30597533|t=2019. Synthetic biology for bioengineering virus-like particle vaccines.|pdf=|usr=013}}
+
−
{{tp|p=26212697|t=2015. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.|pdf=|usr=013}}
+
−
{{tp|p=20809484|t=2010. Generating stable Chinese hamster ovary cell clones to produce a truncated SARS-CoV spike protein for vaccine development.|pdf=|usr=013}}
+
−
{{tp|p=16321039|t=2005. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic.|pdf=|usr=013}}
+
−
{{tp|p=32493296|t=2020. Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia.|pdf=|usr=013}}
+
−
{{tp|p=32601089|t=2020. Food is medicine: actions to integrate food and nutrition into healthcare.|pdf=|usr=013}}
+
−
{{tp|p=32444705|t=2020. Hydrogen peroxide mouthwash.|pdf=|usr=013}}
+
−
{{tp|p=32591697|t=2020. New video will promote silver diamine fluoride to children.|pdf=|usr=013}}
+
−
{{tp|p=32591690|t=2020. Chlorhexidine has an antiviral effect against viruses.|pdf=|usr=013}}
+
−
{{tp|p=32591675|t=2020. Virucidal activity.|pdf=|usr=013}}
+
−
{{tp|p=32591671|t=2020. Povidone iodine gargle and mouthwash.|pdf=|usr=013}}
+
−
{{tp|p=32307721|t=2020. Extensive hard palate hyperpigmentation associated with chloroquine use.|pdf=|usr=013}}
+
−
{{tp|p=32615072|t=2020. Ivermectin: potential candidate for the treatment of Covid 19.|pdf=|usr=013}}
+
−
{{tp|p=32645327|t=2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.|pdf=|usr=013}}
+
−
{{tp|p=32643603|t=2020. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.|pdf=|usr=013}}
+
−
{{tp|p=32442424|t=2020. Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism.|pdf=|usr=013}}
+
−
{{tp|p=32544459|t=2020. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment.|pdf=|usr=013}}
+
−
{{tp|p=32402267|t=2020. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation.|pdf=|usr=013}}
+
−
{{tp|p=32612152|t=2020. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32629149|t=2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=16511823|t=2006. Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141.|pdf=|usr=013}}
+
−
{{tp|p=23788528|t=2013. Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications.|pdf=|usr=013}}
+
−
{{tp|p=32533956|t=2020. Impact of Small-N Studies During a Pandemic.|pdf=|usr=013}}
+
−
{{tp|p=32505301|t=2020. Adjunctive Therapies in ARDS: The Disconnect Between Clinical Trials and Clinical Practice.|pdf=|usr=013}}
+
−
{{tp|p=32632717|t=2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.|pdf=|usr=013}}
+
−
{{tp|p=32405143|t=2020. Remdesivir - A giant step, or a tiptoe?|pdf=|usr=013}}
+
−
{{tp|p=32512231|t=2020. Tuberculosis sepsis after tocilizumab treatment.|pdf=|usr=013}}
+
−
{{tp|p=32651020|t=2020. COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use.|pdf=|usr=013}}
+
−
{{tp|p=32613089|t=2020. Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.|pdf=|usr=013}}
+
−
{{tp|p=32402130|t=2020. What Do We Know About Remdesivir Drug Interactions?|pdf=|usr=013}}
+
−
{{tp|p=32623357|t=2020. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=013}}
+
−
{{tp|p=32661494|t=2020. Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.|pdf=|usr=013}}
+
−
{{tp|p=32653043|t=2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.|pdf=|usr=013}}
+
−
{{tp|p=32653015|t=2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.|pdf=|usr=013}}
+
−
{{tp|p=32426753|t=2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.|pdf=|usr=013}}
+
−
{{tp|p=32637266|t=2020. Lithium Toxicity in Two Coronavirus Disease 2019 (COVID-19) Patients.|pdf=|usr=013}}
+
−
{{tp|p=32626630|t=2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.|pdf=|usr=013}}
+
−
{{tp|p=32637278|t=2020. Packed Red Blood Cell Transfusion as a Potential Treatment Option in COVID-19 Patients With Hypoxemic Respiratory Failure: A Case Report.|pdf=|usr=013}}
+
−
{{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=013}}
+
−
{{tp|p=32615514|t=2020. Docking approaches for modeling multi-molecular assemblies.|pdf=|usr=013}}
+
−
{{tp|p=32399388|t=2020. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.|pdf=|usr=013}}
+
−
{{tp|p=32616467|t=2020. Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy.|pdf=|usr=013}}
+
−
{{tp|p=32616381|t=2020. A critical evaluation of glucocorticoids in the management of severe COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32636055|t=2020. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32227604|t=2020. Repurposing therapeutic agents and herbal medicines to defeat viral nemesis.|pdf=|usr=013}}
+
−
{{tp|p=32655654|t=2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.|pdf=|usr=013}}
+
−
{{tp|p=32636919|t=2020. Can vitamins and/or supplements provide hope against coronavirus?|pdf=|usr=013}}
+
−
{{tp|p=32427191|t=2019. Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination.|pdf=|usr=013}}
+
−
{{tp|p=32619884|t=2020. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?|pdf=|usr=013}}
+
−
{{tp|p=32506216|t=2020. Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase(R).|pdf=|usr=013}}
+
−
{{tp|p=32653152|t=2020. Waste in COVID-19 clinical trials conducted in western Europe.|pdf=|usr=013}}
+
−
{{tp|p=32651040|t=2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.|pdf=|usr=013}}
+
−
{{tp|p=32652408|t=2020. Natural and nature-inspired stilbenoids as antiviral agents.|pdf=|usr=013}}
+
−
{{tp|p=32616594|t=2020. Cyclophilin Inhibitors Restrict Middle East Respiratory Syndrome Coronavirus Via Interferon lambda In Vitro And In Mice.|pdf=|usr=013}}
+
−
{{tp|p=32591664|t=2020. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?|pdf=|usr=013}}
+
−
{{tp|p=32587388|t=2020. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria.|pdf=|usr=013}}
+
−
{{tp|p=32427967|t=2020. Hydroxychloroquine hitting the headlines-retinal considerations.|pdf=|usr=013}}
+
−
{{tp|p=32653511|t=2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32655584|t=2020. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.|pdf=|usr=013}}
+
−
{{tp|p=32655583|t=2020. Vitamin D Supplementation: A Potential Approach for Coronavirus/COVID-19 Therapeutics?|pdf=|usr=013}}
+
−
{{tp|p=32655582|t=2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32655581|t=2020. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.|pdf=|usr=013}}
+
−
{{tp|p=32655578|t=2020. Three Decades of Interferon-beta in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?|pdf=|usr=013}}
+
−
{{tp|p=32655577|t=2020. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.|pdf=|usr=013}}
+
−
{{tp|p=32636851|t=2020. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).|pdf=|usr=013}}
+
−
{{tp|p=32612616|t=2020. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.|pdf=|usr=013}}
+
−
{{tp|p=32612613|t=2020. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.|pdf=|usr=013}}
+
−
{{tp|p=32582186|t=2020. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.|pdf=|usr=013}}
+
−
{{tp|p=32174911|t=2020. Quantitative Proteomic Analysis Reveals Antiviral and Anti-inflammatory Effects of Puerarin in Piglets Infected With Porcine Epidemic Diarrhea Virus.|pdf=|usr=013}}
+
−
{{tp|p=32651936|t=2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.|pdf=|usr=013}}
+
−
{{tp|p=32655532|t=2020. Biocides and Novel Antimicrobial Agents for the Mitigation of Coronaviruses.|pdf=|usr=013}}
+
−
{{tp|p=32636755|t=2020. Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32636754|t=2020. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.|pdf=|usr=013}}
+
−
{{tp|p=32390855|t=2020. Traditional Chinese Medicine and Gut Microbiome: Their Respective and Concert Effects on Healthcare.|pdf=|usr=013}}
+
−
{{tp|p=32636763|t=2020. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease.|pdf=|usr=013}}
+
−
{{tp|p=32636762|t=2020. Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection.|pdf=|usr=013}}
+
−
{{tp|p=32352313|t=2020. Incipient need of targeting airway remodeling using advanced drug delivery in chronic respiratory diseases.|pdf=|usr=013}}
+
−
{{tp|p=32647807|t=2020. The Emerging Role of Convalescent Plasma in the Treatment of COVID-19.|pdf=|usr=013}}
+
−
{{tp|p=32606420|t=2020. The value of targeting recombination as a strategy against coronavirus diseases.|pdf=|usr=013}}
+
  
 +
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
 +
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
 +
based on e.g.
  
−
{{tp|p=32665809|t=2020. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.|pdf=|usr=014}}
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
−
{{tp|p=32665808|t=2020. Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment.|pdf=|usr=014}}
+
−
{{tp|p=32667191|t=2020. Hard Nanomaterials in Time of Viral Pandemics.|pdf=|usr=014}}
+
−
{{tp|p=32717094|t=2020. Cannabis terapeutico y COVID-19: entre el oportunismo y la infoxicacion.|pdf=|usr=014}}
+
−
{{tp|p=32711735|t=2020. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae.|pdf=|usr=014}}
+
−
{{tp|p=32705585|t=2020. Associations between hypovitaminosis D and COVID-19: a narrative review.|pdf=|usr=014}}
+
−
{{tp|p=32653224|t=2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?|pdf=|usr=014}}
+
−
{{tp|p=32687406|t=2020. Inhibiting Fusion with Cellular Membrane System: Therapeutic Options to Prevent Severe Acute Respiratory Syndrome Coronavirus-2 Infection.|pdf=|usr=014}}
+
−
{{tp|p=32653550|t=2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?|pdf=|usr=014}}
+
−
{{tp|p=32673060|t=2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.|pdf=|usr=014}}
+
−
{{tp|p=32673059|t=2020. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.|pdf=|usr=014}}
+
−
{{tp|p=32667853|t=2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32653425|t=2020. Does androgen deprivation therapy protect against severe complications from COVID-19?|pdf=|usr=014}}
+
−
{{tp|p=32692238|t=2020. Tongue diagnosis and treatment in traditional Chinese medicine for severe COVID-19: a case report.|pdf=|usr=014}}
+
−
{{tp|p=32660993|t=2020. Safety, pharmacokinetics, and activity of high-dose ivermectin and chloroquine against the liver-stage of Plasmodium cynomolgi infection in Rhesus Macaques.|pdf=|usr=014}}
+
−
{{tp|p=32708578|t=2020. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32679055|t=2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32659293|t=2020. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.|pdf=|usr=014}}
+
−
{{tp|p=32659292|t=2020. Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.|pdf=|usr=014}}
+
−
{{tp|p=32660794|t=2020. Response to: Amantadine Treatment for People with COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32682671|t=2020. Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.|pdf=|usr=014}}
+
−
{{tp|p=32710969|t=2020. Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32688139|t=2020. PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open.|pdf=|usr=014}}
+
−
{{tp|p=32679775|t=2020. Deamidated Human Triosephosphate Isomerase is a Promising Druggable Target.|pdf=|usr=014}}
+
−
{{tp|p=32665234|t=2020. Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.|pdf=|usr=014}}
+
−
{{tp|p=32717399|t=2020. Purinergic signaling in infectious diseases of the central nervous system.|pdf=|usr=014}}
+
−
{{tp|p=32679175|t=2020. Regional differences in use of immune-modulating catechins should be investigated regarding COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32679174|t=2020. Reply to the Letter to the Editor: Regional differences in dietary use of immune-modulating catechins should be investigated regarding COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32615072|t=2020. Ivermectin: potential candidate for the treatment of Covid 19.|pdf=|usr=014}}
+
−
{{tp|p=32717278|t=2020. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.|pdf=|usr=014}}
+
−
{{tp|p=32643141|t=2020. Ion channel inhibition against COVID-19: A novel target for clinical investigation.|pdf=|usr=014}}
+
−
{{tp|p=32645327|t=2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.|pdf=|usr=014}}
+
−
{{tp|p=32714563|t=2020. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro.|pdf=|usr=014}}
+
−
{{tp|p=32707096|t=2020. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.|pdf=|usr=014}}
+
−
{{tp|p=32668216|t=2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.|pdf=|usr=014}}
+
−
{{tp|p=32711111|t=2020. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.|pdf=|usr=014}}
+
−
{{tp|p=32710890|t=2020. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study.|pdf=|usr=014}}
+
−
{{tp|p=32676976|t=2020. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.|pdf=|usr=014}}
+
−
{{tp|p=32632717|t=2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.|pdf=|usr=014}}
+
−
{{tp|p=32665783|t=2020. Current strategies against COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32667534|t=2020. Pandemia de COVID19: implicacoes para (in)seguranca alimentar e nutricional.|pdf=|usr=014}}
+
−
{{tp|p=32661912|t=2020. Tocilizumab, Adipokines and Severe Complications of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32661911|t=2020. Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32707089|t=2020. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine.|pdf=|usr=014}}
+
−
{{tp|p=32673711|t=2020. mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome.|pdf=|usr=014}}
+
−
{{tp|p=32663514|t=2020. Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'.|pdf=|usr=014}}
+
−
{{tp|p=32675166|t=2020. COVID-19, hydroxychloroquine and the eighth alternative.|pdf=|usr=014}}
+
−
{{tp|p=32717568|t=2020. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.|pdf=|usr=014}}
+
−
{{tp|p=32705604|t=2020. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?|pdf=|usr=014}}
+
−
{{tp|p=32709544|t=2020. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.|pdf=|usr=014}}
+
−
{{tp|p=32668460|t=2020. COVID-19 Therapeutics: Making Sense of It All.|pdf=|usr=014}}
+
−
{{tp|p=32662982|t=2020. Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection.|pdf=|usr=014}}
+
−
{{tp|p=32687696|t=2020. Old drugs for a new virus: repurposed approaches for combating COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32686128|t=2020. Montelukast in children with allergic rhinitis amid COVID-19 pandemic.|pdf=|usr=014}}
+
−
{{tp|p=32696443|t=2020. The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.|pdf=|usr=014}}
+
−
{{tp|p=32716768|t=2020. The Regulation of COVID-19 "Challenge" Studies.|pdf=|usr=014}}
+
−
{{tp|p=32709838|t=2020. Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C.|pdf=|usr=014}}
+
−
{{tp|p=32661220|t=2020. First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection.|pdf=|usr=014}}
+
−
{{tp|p=32694294|t=2020. Nutrition Support in the ICU-A Refresher in the Era of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32668178|t=2020. Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32668164|t=2020. Reply to: Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32711585|t=2020. More Studies are Needed on the Link between Metformin and Decreased Mortality in Diabetic COVID-19 Patients.|pdf=|usr=014}}
+
−
{{tp|p=32705976|t=2020. Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials.|pdf=|usr=014}}
+
−
{{tp|p=32663348|t=2020. Current status of COVID-19 (pre)clinical vaccine development.|pdf=|usr=014}}
+
−
{{tp|p=32692580|t=2020. Repurposing Existing Drugs for the Treatment of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32687756|t=2020. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.|pdf=|usr=014}}
+
−
{{tp|p=32661006|t=2020. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.|pdf=|usr=014}}
+
−
{{tp|p=32686943|t=2020. Potential role of Bacillus Calmette-Guerin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects.|pdf=|usr=014}}
+
−
{{tp|p=32713288|t=2020. Chloroquine in fighting COVID-19: good, bad, or both?|pdf=|usr=014}}
+
−
{{tp|p=32692801|t=2020. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32663708|t=2020. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M(pro)) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.|pdf=|usr=014}}
+
−
{{tp|p=32699011|t=2020. Intensive immunosuppression reduces deaths in covid-19-associated cytokine storm syndrome, study finds.|pdf=|usr=014}}
+
−
{{tp|p=32698999|t=2020. Are we responsible for the racial inequalities of covid-19?|pdf=|usr=014}}
+
−
{{tp|p=32665225|t=2020. Covid-19: Experts criticise claim that remdesivir cuts death rates.|pdf=|usr=014}}
+
−
{{tp|p=32693436|t=2020. Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32692462|t=2020. ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32687645|t=2020. Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin.|pdf=|usr=014}}
+
−
{{tp|p=32656822|t=2020. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.|pdf=|usr=014}}
+
−
{{tp|p=32652563|t=2020. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.|pdf=|usr=014}}
+
−
{{tp|p=32713358|t=2020. COVID-19 and Misinformation: How an Infodemic Fueled the prominence of Vitamin D.|pdf=|usr=014}}
+
−
{{tp|p=32703328|t=2020. THE RATIONALE FOR A MULTI-STEP THERAPEUTIC APPROACH BASED ON ANTIVIRALS, DRUGS, AND NUTRIENTS WITH IMMUNOMODULATORY ACTIVITY IN PATIENTS WITH CORONAVIRUS-SARS2-INDUCED DISEASE OF DIFFERENT SEVERITY.|pdf=|usr=014}}
+
−
{{tp|p=32700336|t=2020. Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32681537|t=2020. Safety perspectives on presently considered drugs for the treatment of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32671829|t=2020. Targeting zinc metalloenzymes in COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32713374|t=2020. Clozapine treatment and risk of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32662814|t=2020. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses.|pdf=|usr=014}}
+
−
{{tp|p=32717117|t=2020. Peptidyl Acyloxymethyl Ketones as Activity-Based Probes for the Main Protease of SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32700795|t=2020. Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators.|pdf=|usr=014}}
+
−
{{tp|p=32702997|t=2020. IL-6 Blockade and QTc Prolongation in COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32671847|t=2020. In response to: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.|pdf=|usr=014}}
+
−
{{tp|p=32710937|t=2020. Micronutrients as immunomodulatory tools for COVID-19 management.|pdf=|usr=014}}
+
−
{{tp|p=32706859|t=2020. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.|pdf=|usr=014}}
+
−
{{tp|p=32674126|t=2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.|pdf=|usr=014}}
+
−
{{tp|p=32671407|t=2020. Long-term outcome of short-course high-dose glucocorticoids for SARS: a 17-year follow-up in SARS survivors.|pdf=|usr=014}}
+
−
{{tp|p=32667978|t=2020. Treatment of COVID-19 - Evidence-Based or Personalized Medicine?|pdf=|usr=014}}
+
−
{{tp|p=32651997|t=2020. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32687630|t=2020. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.|pdf=|usr=014}}
+
−
{{tp|p=32674594|t=2020. Endpoints for randomized controlled clinical trials for COVID-19 treatments.|pdf=|usr=014}}
+
−
{{tp|p=32666816|t=2020. Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.|pdf=|usr=014}}
+
−
{{tp|p=32650672|t=2020. Clinical trials in the time of a pandemic.|pdf=|usr=014}}
+
−
{{tp|p=32650671|t=2020. Editorial: Clinical trial design in the era of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32651961|t=2020. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.|pdf=|usr=014}}
+
−
{{tp|p=32675717|t=2020. Role for antimalarials in the management of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32674732|t=2020. Ligand- and structure-based virtual screening of Lamiaceae diterpenes with potential activity against a novel coronavirus (2019-nCoV).|pdf=|usr=014}}
+
−
{{tp|p=32686260|t=2020. Insights in chloroquine action: perspectives and implications in Malaria and COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32692700|t=2020. Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?|pdf=|usr=014}}
+
−
{{tp|p=32690491|t=2020. Dexamethasone for COVID-19: preliminary findings.|pdf=|usr=014}}
+
−
{{tp|p=32705683|t=2020. High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection.|pdf=|usr=014}}
+
−
{{tp|p=32688337|t=2020. Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues.|pdf=|usr=014}}
+
−
{{tp|p=32706089|t=2020. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32706087|t=2020. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.|pdf=|usr=014}}
+
−
{{tp|p=32700604|t=2020. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.|pdf=|usr=014}}
+
  
−
{{tp|p=32658735|t=2020. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.|pdf=|usr=014}}
+
=======================================================================================
−
{{tp|p=32698853|t=2020. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.|pdf=|usr=014}}
+
−
{{tp|p=32693829|t=2020. Chinese herbal experience for the 2019 novel coronavirus.|pdf=|usr=014}}
+
−
{{tp|p=32690059|t=2020. Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials.|pdf=|usr=014}}
+
−
{{tp|p=32684169|t=2020. Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study.|pdf=|usr=014}}
+
−
{{tp|p=32682440|t=2020. Blocking IL-1 to prevent respiratory failure in COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32680535|t=2020. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.|pdf=|usr=014}}
+
−
{{tp|p=32664996|t=2020. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation.|pdf=|usr=014}}
+
−
{{tp|p=32653043|t=2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.|pdf=|usr=014}}
+
−
{{tp|p=32653015|t=2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.|pdf=|usr=014}}
+
−
{{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=014}}
+
−
{{tp|p=32661859|t=2020. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?|pdf=|usr=014}}
+
−
{{tp|p=32665127|t=2020. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?|pdf=|usr=014}}
+
−
{{tp|p=32683320|t=2020. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).|pdf=|usr=014}}
+
−
{{tp|p=32696429|t=2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.|pdf=|usr=014}}
+
−
{{tp|p=32696108|t=2020. Pharmaco-Immunomodulatory Therapy in COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32655654|t=2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.|pdf=|usr=014}}
+
−
{{tp|p=32691021|t=2020. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia.|pdf=|usr=014}}
+
−
{{tp|p=32662949|t=2020. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.|pdf=|usr=014}}
+
−
{{tp|p=32696234|t=2020. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.|pdf=|usr=014}}
+
−
{{tp|p=32653152|t=2020. Waste in COVID-19 clinical trials conducted in western Europe.|pdf=|usr=014}}
+
−
{{tp|p=32651040|t=2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.|pdf=|usr=014}}
+
−
{{tp|p=32693294|t=2020. Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.|pdf=|usr=014}}
+
−
{{tp|p=32668312|t=2020. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection.|pdf=|usr=014}}
+
−
{{tp|p=32682787|t=2020. Advances in the possible treatment of COVID-19: A review.|pdf=|usr=014}}
+
−
{{tp|p=32700671|t=2020. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32707160|t=2020. An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.|pdf=|usr=014}}
+
−
{{tp|p=32679367|t=2020. Selenium - associated gene signatures within the SARS-CoV-2 - host genomic interaction interface.|pdf=|usr=014}}
+
−
{{tp|p=32653511|t=2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32714335|t=2020. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.|pdf=|usr=014}}
+
−
{{tp|p=32695123|t=2020. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.|pdf=|usr=014}}
+
−
{{tp|p=32670297|t=2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.|pdf=|usr=014}}
+
−
{{tp|p=32705405|t=2020. Traditional Chinese medicine for combating COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32651936|t=2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.|pdf=|usr=014}}
+
−
{{tp|p=32714938|t=2020. Physical Exercise Potentials Against Viral Diseases Like COVID-19 in the Elderly.|pdf=|usr=014}}
+
−
{{tp|p=32671084|t=2020. Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol.|pdf=|usr=014}}
+
−
{{tp|p=32714193|t=2020. Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection.|pdf=|usr=014}}
+
−
{{tp|p=32698626|t=2020. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives.|pdf=|usr=014}}
+
−
{{tp|p=32672061|t=2020. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.|pdf=|usr=014}}
+
−
{{tp|p=32662664|t=2020. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019.|pdf=|usr=014}}
+
−
{{tp|p=32682763|t=2020. Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study.|pdf=|usr=014}}
+
−
{{tp|p=32717321|t=2020. Genomics approaches to synthesis plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32703797|t=2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.|pdf=|usr=014}}
+
−
{{tp|p=32703791|t=2020. Complement C5 inhibition in patients with COVID-19 - a promising target?|pdf=|usr=014}}
+
−
{{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=014}}
+
−
{{tp|p=32712334|t=2020. Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study.|pdf=|usr=014}}
+
−
{{tp|p=32712333|t=2020. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.|pdf=|usr=014}}
+
−
{{tp|p=32708322|t=2020. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?|pdf=|usr=014}}
+
−
{{tp|p=32717282|t=2020. The Lord of the NanoRings: cyclodextrins and the battle against SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32711037|t=2020. Radiation Therapy as a Treatment for COVID-19?|pdf=|usr=014}}
+
−
{{tp|p=32707264|t=2020. Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Short Course Results.|pdf=|usr=014}}
+
−
{{tp|p=32713677|t=2020. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.|pdf=|usr=014}}
+
−
{{tp|p=32707230|t=2020. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: implications for treatment with IFN-beta and IFN inducer.|pdf=|usr=014}}
+
−
{{tp|p=32662677|t=2020. The combination of artificial intelligence and systems biology for intelligent vaccine design.|pdf=|usr=014}}
+
−
{{tp|p=32693646|t=2020. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.|pdf=|usr=014}}
+
−
{{tp|p=32693650|t=2020. Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study.|pdf=|usr=014}}
+
−
{{tp|p=32693652|t=2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.|pdf=|usr=014}}
+
−
{{tp|p=32662690|t=2020. The Use of IV vitamin C for patients with COVID-19: a single center observational study.|pdf=|usr=014}}
+
−
{{tp|p=32700398|t=2020. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.|pdf=|usr=014}}
+
−
{{tp|p=32657483|t=2020. Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.|pdf=|usr=014}}
+
−
{{tp|p=32691927|t=2020. Drug interactions with potential antivirals used for COVID-19 in older persons.|pdf=|usr=014}}
+
−
{{tp|p=32701395|t=2020. Designing Pull Funding For A COVID-19 Vaccine.|pdf=|usr=014}}
+
−
{{tp|p=32706599|t=2020. A Social and Behavioral Research Agenda to Facilitate COVID-19 Vaccine Uptake in the United States.|pdf=|usr=014}}
+
−
{{tp|p=32703069|t=2020. Promise and challenges in the development of COVID-19 vaccines.|pdf=|usr=014}}
+
−
{{tp|p=32703064|t=2020. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines.|pdf=|usr=014}}
+
−
{{tp|p=32693665|t=2020. COVID-19 - Important considerations for developing and using a vaccine.|pdf=|usr=014}}
+
−
{{tp|p=32663051|t=2020. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.|pdf=|usr=014}}
+
−
{{tp|p=32710535|t=2020. MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?|pdf=|usr=014}}
+
−
{{tp|p=32713336|t=2020. Chloroquine as chemoprophylaxis for COVID-19: Will this work?|pdf=|usr=014}}
+
−
{{tp|p=32673140|t=2020. Re: Low-dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?|pdf=|usr=014}}
+
−
{{tp|p=32674673|t=2020. COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?|pdf=|usr=014}}
+
−
{{tp|p=32666683|t=2020. COVID-19 and chronic obstructive pulmonary disease: therapeutic potential of blocking SARS-CoV2 adhesion factors.|pdf=|usr=014}}
+
−
{{tp|p=32673081|t=2020. Chinese Herbal Medicines During the Covid-19 Pandemic: A Role for Observational Studies.|pdf=|usr=014}}
+
−
{{tp|p=32659175|t=2020. Can Vitamin D and L-Cysteine Co-Supplementation Reduce 25(OH)-Vitamin D Deficiency and the Mortality Associated with COVID-19 in African Americans?|pdf=|usr=014}}
+
−
{{tp|p=32688374|t=2020. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.|pdf=|usr=014}}
+
−
{{tp|p=32720578|t=2020. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.|pdf=|usr=014}}
+
−
{{tp|p=32720577|t=2020. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis.|pdf=|usr=014}}
+
−
{{tp|p=32720571|t=2020. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32715956|t=2020. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32705962|t=2020. Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32705953|t=2020. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.|pdf=|usr=014}}
+
−
{{tp|p=32705952|t=2020. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M(pro)) from flavonoid based phytochemical constituents of Calendula officinalis.|pdf=|usr=014}}
+
−
{{tp|p=32705942|t=2020. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.|pdf=|usr=014}}
+
−
{{tp|p=32698693|t=2020. Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads.|pdf=|usr=014}}
+
−
{{tp|p=32698689|t=2020. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development.|pdf=|usr=014}}
+
−
{{tp|p=32696720|t=2020. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32696718|t=2020. Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular docking study.|pdf=|usr=014}}
+
−
{{tp|p=32692306|t=2020. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.|pdf=|usr=014}}
+
−
{{tp|p=32691697|t=2020. Natural derivatives with dual binding potential against SARS-CoV-2 main protease and human ACE2 possess low oral bioavailability: a brief computational analysis.|pdf=|usr=014}}
+
−
{{tp|p=32691680|t=2020. Cyanobacterial metabolites as promising drug leads against the M(pro) and PL(pro) of SARS-CoV-2: an in silico analysis.|pdf=|usr=014}}
+
−
{{tp|p=32684114|t=2020. In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=014}}
+
−
{{tp|p=32684109|t=2020. Targeting virus-host interaction by novel pyrimidine derivative: an in silico approach towards discovery of potential drug against COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32679006|t=2020. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL(pro)).|pdf=|usr=014}}
+
−
{{tp|p=32677591|t=2020. The latitude hypothesis, vitamin D, and SARS-Co-V2.|pdf=|usr=014}}
+
−
{{tp|p=32677545|t=2020. Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study.|pdf=|usr=014}}
+
−
{{tp|p=32677533|t=2020. Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach.|pdf=|usr=014}}
+
−
{{tp|p=32672528|t=2020. Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches.|pdf=|usr=014}}
+
−
{{tp|p=32666910|t=2020. Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies.|pdf=|usr=014}}
+
−
{{tp|p=32662333|t=2020. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.|pdf=|usr=014}}
+
−
{{tp|p=32657643|t=2020. Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1).|pdf=|usr=014}}
+
−
{{tp|p=32697000|t=2020. Corticosteroids-induced osteonecrosis in COVID-19: a call for caution.|pdf=|usr=014}}
+
−
{{tp|p=32658005|t=2020. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.|pdf=|usr=014}}
+
−
{{tp|p=32700555|t=2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.|pdf=|usr=014}}
+
−
{{tp|p=32692858|t=2020. Stem cell therapies for COVID-19: Strategy and application.|pdf=|usr=014}}
+
−
{{tp|p=32687345|t=2020. Structure-based virtual screening to discover potential lead molecules for the SARS-CoV-2 main protease.|pdf=|usr=014}}
+
−
{{tp|p=32678588|t=2020. SARS-CoV-2 Main Protease: A Molecular Dynamics Study.|pdf=|usr=014}}
+
−
{{tp|p=32694358|t=2020. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.|pdf=|usr=014}}
+
−
{{tp|p=32700580|t=2020. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.|pdf=|usr=014}}
+
−
{{tp|p=32677610|t=2020. Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro.|pdf=|usr=014}}
+
−
{{tp|p=32651218|t=2020. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.|pdf=|usr=014}}
+
−
{{tp|p=32702095|t=2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.|pdf=|usr=014}}
+
−
{{tp|p=32651586|t=2020. Do Not Minimize the Impact of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.|pdf=|usr=014}}
+
  
−
{{tp|p=32666357|t=2020. Vitamin D and COVID-19.|pdf=|usr=014}}
+
COVID19 is now a CURABLE disease !!!
−
{{tp|p=32685369|t=2020. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.|pdf=|usr=014}}
+
−
{{tp|p=32677493|t=2020. Obesity, COVID-19 and immunotherapy: the complex relationship!|pdf=|usr=014}}
+
−
{{tp|p=32664810|t=2020. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.|pdf=|usr=014}}
+
−
{{tp|p=32651941|t=2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32656668|t=2020. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.|pdf=|usr=014}}
+
−
{{tp|p=32683296|t=2020. Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.|pdf=|usr=014}}
+
−
{{tp|p=32687949|t=2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.|pdf=|usr=014}}
+
−
{{tp|p=32674929|t=2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?|pdf=|usr=014}}
+
−
{{tp|p=32674928|t=2020. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.|pdf=|usr=014}}
+
−
{{tp|p=32693122|t=2020. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.|pdf=|usr=014}}
+
−
{{tp|p=32682041|t=2020. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach.|pdf=|usr=014}}
+
−
{{tp|p=32698494|t=2020. Self-Amplifying RNA Viruses as RNA Vaccines.|pdf=|usr=014}}
+
−
{{tp|p=32674481|t=2020. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.|pdf=|usr=014}}
+
−
{{tp|p=32691002|t=2020. A consensus guideline of herbal medicine for coronavirus disease 2019.|pdf=|usr=014}}
+
−
{{tp|p=32691000|t=2020. Herbal medicine for the management of COVID-19 during the medical observation period: A review of guidelines.|pdf=|usr=014}}
+
−
{{tp|p=32652231|t=2020. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.|pdf=|usr=014}}
+
−
{{tp|p=32652194|t=2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.|pdf=|usr=014}}
+
−
{{tp|p=32674834|t=2020. Plasma Therapies and Parabiosis in the COVID-19 Era.|pdf=|usr=014}}
+
−
{{tp|p=32690352|t=2020. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.|pdf=|usr=014}}
+
−
{{tp|p=32694923|t=2020. Blood Targets of Adjuvant Drugs Against COVID19.|pdf=|usr=014}}
+
−
{{tp|p=32713161|t=2020. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.|pdf=|usr=014}}
+
−
{{tp|p=32677763|t=2020. Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!|pdf=|usr=014}}
+
−
{{tp|p=32672454|t=2020. Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs.|pdf=|usr=014}}
+
−
{{tp|p=32655741|t=2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.|pdf=|usr=014}}
+
−
{{tp|p=32683212|t=2020. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32680687|t=2020. Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome.|pdf=|usr=014}}
+
−
{{tp|p=32682930|t=2020. Could Bordetella pertussis vaccine protect against coronavirus COVID-19?|pdf=|usr=014}}
+
−
{{tp|p=32695833|t=2020. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.|pdf=|usr=014}}
+
−
{{tp|p=32652164|t=2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.|pdf=|usr=014}}
+
−
{{tp|p=32666875|t=2020. Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.|pdf=|usr=014}}
+
−
{{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=014}}
+
−
{{tp|p=32661074|t=2020. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.|pdf=|usr=014}}
+
−
{{tp|p=32702590|t=2020. Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation.|pdf=|usr=014}}
+
−
{{tp|p=32682142|t=2020. Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists.|pdf=|usr=014}}
+
−
{{tp|p=32684166|t=2020. Withaferin A: a potential therapeutic agent against COVID-19 infection.|pdf=|usr=014}}
+
−
{{tp|p=32685234|t=2020. Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?|pdf=|usr=014}}
+
−
{{tp|p=32658489|t=2020. Michael Acceptors Tuned by the Pivotal Aromaticity of Histidine to Block COVID-19 Activity.|pdf=|usr=014}}
+
−
{{tp|p=32653646|t=2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.|pdf=|usr=014}}
+
−
{{tp|p=32718719|t=2020. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.|pdf=|usr=014}}
+
−
{{tp|p=32718715|t=2020. Reacciones adversas a farmacos utilizados en el tratamiento especifico de la infeccion por SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32712223|t=2020. Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action.|pdf=|usr=014}}
+
−
{{tp|p=32712272|t=2020. Blood nitrate and nitrite modulating nitric oxide bioavailability: potential therapeutic functions in COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32708526|t=2020. Selenium Deficiency Is Associated with Mortality Risk from COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32709055|t=2020. Polymorphism and Selection Pressure of SARS-CoV-2 Vaccine and Diagnostic Antigens: Implications for Immune Evasion and Serologic Diagnostic Performance.|pdf=|usr=014}}
+
−
{{tp|p=32707768|t=2020. Two Examples of RNA Aptamers with Antiviral Activity. Are Aptamers the Wished Antiviral Drugs?|pdf=|usr=014}}
+
−
{{tp|p=32713784|t=2020. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.|pdf=|usr=014}}
+
−
{{tp|p=32703528|t=2020. Replica: Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?|pdf=|usr=014}}
+
−
{{tp|p=32719454|t=2020. Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates.|pdf=|usr=014}}
+
−
{{tp|p=32652766|t=2020. The link between Vitamin D and Covid-19: distinguishing facts from fiction.|pdf=|usr=014}}
+
−
{{tp|p=32662708|t=2020. SARS-CoV-2 in the first trimester of pregnancy: potential interference in placentation.|pdf=|usr=014}}
+
−
{{tp|p=32692176|t=2020. Lung protection by cathepsin C inhibition: a new hope for COVID-19 and ARDS?|pdf=|usr=014}}
+
−
{{tp|p=32716073|t=2020. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients.|pdf=|usr=014}}
+
−
{{tp|p=32691896|t=2020. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.|pdf=|usr=014}}
+
−
{{tp|p=32691875|t=2020. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.|pdf=|usr=014}}
+
−
{{tp|p=32681650|t=2020. SARS-CoV-2 replicating in non-primate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.|pdf=|usr=014}}
+
−
{{tp|p=32672860|t=2020. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.|pdf=|usr=014}}
+
−
{{tp|p=32658304|t=2020. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).|pdf=|usr=014}}
+
−
{{tp|p=32651248|t=2020. Management of patients with generalised myasthenia gravis and COVID-19: four case reports.|pdf=|usr=014}}
+
−
{{tp|p=32680924|t=2020. Oncology-inspired treatment options for COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32710111|t=2020. Vitamin D and COVID-19: Lessons from Spaceflight Analogs.|pdf=|usr=014}}
+
−
{{tp|p=32705690|t=2020. Benzothiazoles as potential antiviral agents.|pdf=|usr=014}}
+
−
{{tp|p=32650355|t=2020. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept.|pdf=|usr=014}}
+
−
{{tp|p=32699094|t=2020. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.|pdf=|usr=014}}
+
−
{{tp|p=32675436|t=2020. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.|pdf=|usr=014}}
+
−
{{tp|p=32717043|t=2020. Pooling Data From Individual Clinical Trials in the COVID-19 Era.|pdf=|usr=014}}
+
−
{{tp|p=32662848|t=2020. COVID-19 Antibody Trials Have Begun.|pdf=|usr=014}}
+
−
{{tp|p=32716474|t=2020. Setting Expectations for Clinical Research During the COVID-19 Pandemic.|pdf=|usr=014}}
+
−
{{tp|p=32720612|t=2020. [Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)].|pdf=|usr=014}}
+
−
{{tp|p=32702300|t=2020. Encouraging results from phase 1/2 COVID-19 vaccine trials.|pdf=|usr=014}}
+
−
{{tp|p=32702299|t=2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.|pdf=|usr=014}}
+
−
{{tp|p=32663575|t=2020. Tackling the cytokine storm in COVID-19, challenges and hopes.|pdf=|usr=014}}
+
−
{{tp|p=32720605|t=2020. In silico study to evaluate the antiviral activity of novel structures against 3C-like protease of Novel Coronavirus (COVID-19) and SARS-CoV.|pdf=|usr=014}}
+
−
{{tp|p=32679430|t=2020. Eicosapentaenoic free fatty acid to treat patients with SARS-Cov2 infection.|pdf=|usr=014}}
+
−
{{tp|p=32678815|t=2020. Lopinavir-ritonavir para COVID-19: una revision sistematica viva.|pdf=|usr=014}}
+
−
{{tp|p=32721082|t=2020. A Computational Approach to Identify Potential Novel Inhibitors against the Coronavirus SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32696772|t=2020. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.|pdf=|usr=014}}
+
−
{{tp|p=32658332|t=2020. COVID-19 in MuSK Myasthenia Gravis: A Case Report.|pdf=|usr=014}}
+
−
{{tp|p=32706953|t=2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.|pdf=|usr=014}}
+
−
{{tp|p=32706553|t=2020. Audio Interview: Dexamethasone and Covid-19.|pdf=|usr=014}}
+
−
{{tp|p=32678530|t=2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.|pdf=|usr=014}}
+
−
{{tp|p=32668131|t=2020. Audio Interview: Covid-19 Vaccine Development.|pdf=|usr=014}}
+
−
{{tp|p=32668109|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.|pdf=|usr=014}}
+
−
{{tp|p=32668108|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
+
−
{{tp|p=32668107|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
+
−
{{tp|p=32668106|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
+
−
{{tp|p=32669667|t=2020. How computational immunology changed the face of COVID-19 vaccine development.|pdf=|usr=014}}
+
−
{{tp|p=32651581|t=2020. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.|pdf=|usr=014}}
+
−
{{tp|p=32669664|t=2020. COVID-19 vaccine development and a potential nanomaterial path forward.|pdf=|usr=014}}
+
−
{{tp|p=32699321|t=2020. Controlling the SARS-CoV-2 spike glycoprotein conformation.|pdf=|usr=014}}
+
−
{{tp|p=32661423|t=2020. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.|pdf=|usr=014}}
+
−
{{tp|p=32707573|t=2020. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.|pdf=|usr=014}}
+
−
{{tp|p=32698191|t=2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.|pdf=|usr=014}}
+
−
{{tp|p=32698190|t=2020. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32668443|t=2020. Potently neutralizing and protective human antibodies against SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32694847|t=2020. Coronavirus vaccines get a biotech boost.|pdf=|usr=014}}
+
−
{{tp|p=32667989|t=2020. COVID-19 and tobacco - more questions than answers.|pdf=|usr=014}}
+
−
{{tp|p=32679589|t=2020. Supplementation with vitamin D in the COVID-19 pandemic?|pdf=|usr=014}}
+
−
{{tp|p=32653930|t=2020. Dietary recommendations during the COVID-19 pandemic.|pdf=|usr=014}}
+
−
{{tp|p=32677126|t=2020. Efficacy of povidone-iodine to reduce viral load.|pdf=|usr=014}}
+
−
{{tp|p=32660339|t=2020. Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review.|pdf=|usr=014}}
+
−
{{tp|p=32677113|t=2020. The cardiovascular effects of treatment with hydroxychloroquine and azithromycin.|pdf=|usr=014}}
+
−
{{tp|p=32674177|t=2020. Therapie mit Dexamethason bei Patienten mit COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32674189|t=2020. DZK-Stellungnahme zu Tuberkulose, BCG und COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32699149|t=2020. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32699147|t=2020. Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.|pdf=|usr=014}}
+
−
{{tp|p=32662915|t=2020. Computer modelling of a potential agent against SARS-Cov-2 (COVID-19) protease.|pdf=|usr=014}}
+
−
{{tp|p=32696570|t=2020. Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state.|pdf=|usr=014}}
+
−
{{tp|p=32698247|t=2020. The effect of BCG vaccine in the era of COVID-19 pandemic.|pdf=|usr=014}}
+
−
{{tp|p=32657436|t=2020. Can medicinal mushrooms have prophylactic or therapeutic effect against COVID-19 and its pneumonic superinfection and complicating inflammation?|pdf=|usr=014}}
+
−
{{tp|p=32720847|t=2020. Is there really room for anti-rheumatic drugs in the treatment of COVID-19?|pdf=|usr=014}}
+
−
{{tp|p=32690628|t=2020. An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.|pdf=|usr=014}}
+
  
−
{{tp|p=32691006|t=2020. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective.|pdf=|usr=014}}
+
=======================================================================================
−
{{tp|p=32691005|t=2020. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?|pdf=|usr=014}}
+
−
{{tp|p=32650788|t=2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.|pdf=|usr=014}}
+
−
{{tp|p=32682081|t=2020. Fish Oil and Covid-19 Thromboses.|pdf=|usr=014}}
+
−
{{tp|p=32661140|t=2020. The SARS-CoV-2 N protein is a good component in a vaccine.|pdf=|usr=014}}
+
−
{{tp|p=32687267|t=2020. Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns.|pdf=|usr=014}}
+
−
{{tp|p=32702298|t=2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.|pdf=|usr=014}}
+
−
{{tp|p=32653520|t=2020. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.|pdf=|usr=014}}
+
−
{{tp|p=32679150|t=2020. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.|pdf=|usr=014}}
+
−
{{tp|p=32679148|t=2020. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.|pdf=|usr=014}}
+
−
{{tp|p=32684816|t=2020. Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections?|pdf=|usr=014}}
+
−
{{tp|p=32703911|t=2020. Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?|pdf=|usr=014}}
+
−
{{tp|p=32663741|t=2020. Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate.|pdf=|usr=014}}
+
−
{{tp|p=32683221|t=2020. Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll.|pdf=|usr=014}}
+
−
{{tp|p=32653736|t=2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.|pdf=|usr=014}}
+
−
{{tp|p=32683219|t=2020. Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32670526|t=2020. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.|pdf=|usr=014}}
+
−
{{tp|p=32668701|t=2020. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32663912|t=2020. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.|pdf=|usr=014}}
+
−
{{tp|p=32663910|t=2020. The Covid-19 Vaccine-Development Multiverse.|pdf=|usr=014}}
+
−
{{tp|p=32665542|t=2020. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.|pdf=|usr=014}}
+
−
{{tp|p=32661375|t=2020. Immune-mediated approaches against COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32694244|t=2020. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.|pdf=|usr=014}}
+
−
{{tp|p=32681986|t=2020. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32655899|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=014}}
+
−
{{tp|p=32679784|t=2020. Immunologic Effects of Vitamin D on Human Health and Disease.|pdf=|usr=014}}
+
−
{{tp|p=32691007|t=2020. Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.|pdf=|usr=014}}
+
−
{{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32704455|t=2020. Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide.|pdf=|usr=014}}
+
−
{{tp|p=32700247|t=2020. Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32653650|t=2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32653649|t=2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.|pdf=|usr=014}}
+
−
{{tp|p=32675044|t=2020. Contribution of traditional Chinese medicine to the treatment of COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32706790|t=2020. Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios.|pdf=|usr=014}}
+
−
{{tp|p=32706783|t=2020. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.|pdf=|usr=014}}
+
−
{{tp|p=32701969|t=2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.|pdf=|usr=014}}
+
−
{{tp|p=32661586|t=2020. COVID-19 and purinergic signaling: the need for investigation.|pdf=|usr=014}}
+
−
{{tp|p=32702730|t=2020. In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data.|pdf=|usr=014}}
+
−
{{tp|p=32702732|t=2020. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.|pdf=|usr=014}}
+
−
{{tp|p=32702715|t=2020. Worldwide inverse correlation between Bacille Calmette-Guerin immunization and COVID-19 morbidity and mortality.|pdf=|usr=014}}
+
−
{{tp|p=32702731|t=2020. Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.|pdf=|usr=014}}
+
−
{{tp|p=32670785|t=2020. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.|pdf=|usr=014}}
+
−
{{tp|p=32659271|t=2020. Pros and cons of corticosteroid therapy for COVID-19 patients.|pdf=|usr=014}}
+
−
{{tp|p=32696884|t=2020. Effects of four types of integrated Chinese and Western medicines for the treatment of COVID-19 in China: a network meta-analysis.|pdf=|usr=014}}
+
−
{{tp|p=32696862|t=2020. Use of remdesivir for patients with Covid-19: a review article.|pdf=|usr=014}}
+
−
{{tp|p=32696811|t=2020. Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports.|pdf=|usr=014}}
+
−
{{tp|p=32691011|t=2020. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.|pdf=|usr=014}}
+
−
{{tp|p=32661235|t=2020. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.|pdf=|usr=014}}
+
−
{{tp|p=32660307|t=2020. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.|pdf=|usr=014}}
+
−
{{tp|p=32695804|t=2020. Cellular Therapy: Shafts of Light Emerging for COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32698898|t=2020. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32678017|t=2020. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.|pdf=|usr=014}}
+
−
{{tp|p=32696426|t=2020. Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.|pdf=|usr=014}}
+
−
{{tp|p=32661867|t=2020. Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32641644|t=2020. COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance?|pdf=|usr=014}}
+
−
{{tp|p=32653199|t=2020. Immunomodulation for the management of corona virus disease (COVID-19).|pdf=|usr=014}}
+
−
{{tp|p=32631501|t=2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?|pdf=|usr=014}}
+
−
{{tp|p=32620409|t=2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.|pdf=|usr=014}}
+
−
{{tp|p=32694044|t=2020. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.|pdf=|usr=014}}
+
−
{{tp|p=32694043|t=2020. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.|pdf=|usr=014}}
+
−
{{tp|p=32684483|t=2020. A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence-FAST Evidence.|pdf=|usr=014}}
+
−
{{tp|p=32660611|t=2020. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=014}}
+
−
{{tp|p=32682360|t=2020. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.|pdf=|usr=014}}
+
−
{{tp|p=32654907|t=2020. Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.|pdf=|usr=014}}
+
−
{{tp|p=32653276|t=2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.|pdf=|usr=014}}
+
−
{{tp|p=32620375|t=2020. Contingent assessment of the COVID-19 vaccine.|pdf=|usr=014}}
+
−
{{tp|p=32684499|t=2020. Planning for COVID-19 vaccines safety surveillance.|pdf=|usr=014}}
+
−
{{tp|p=32698423|t=2020. Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development.|pdf=|usr=014}}
+
−
{{tp|p=32664505|t=2020. Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis.|pdf=|usr=014}}
+
−
{{tp|p=32666898|t=2020. Images in Vascular Medicine: Peripheral artery thrombosis in critically ill patients with COVID-19.|pdf=|usr=014}}
+
−
{{tp|p=32691699|t=2020. Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.|pdf=|usr=014}}
+
−
{{tp|p=32696396|t=2020. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.|pdf=|usr=014}}
+
−
{{tp|p=32698440|t=2020. Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis.|pdf=|usr=014}}
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers 
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development 


PHA related options:



A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets 
=======================================================================================

COVID19 is now a CURABLE disease !!!

=======================================================================================

Von „http://coviki.org/cov/index.php?title=Candidate_Compounds_Covid19&oldid=677958“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis